Pathology Translational Technology Platform, Cancer Institute, University College London London UK UCL/UCLH Biobank for Studying Health and Disease, Cancer Institute, University College London London WC1E 6DE UK.
UCL/UCLH Biobank for Studying Health and Disease, Cancer Institute, University College London London WC1E 6DE UK.
J Biomol Tech. 2022 Feb 2;33(1). doi: 10.7171/3fc1f5fe.a423c94f. eCollection 2022 Apr 15.
Financial sustainability in biobanks has recently become a key issue globally, as biorepositories struggle to balance limited external funding and high operating costs. To maximize governance and operational efficiency, the Pathology Facility and the University College London (UCL)/UCL Hospitals Biobank for Studying Health and Disease ("the Biobank") have been grouped together under the same management at the UCL Cancer Institute. This paper explores the operational and financial interaction between the Pathology Facility and the Biobank over a period of 3 years (2017-2019). Since 2017, only a minority of the requests included collection of samples from the archive or molecular biology services, and most of the requests included histology services. Our data confirmed the difficulty for a biobank to achieve financial sustainability. The integration of the Pathology Facility with the Biobank within a single laboratory management and delivery infrastructure was shown to be an effective management option and presented a unique opportunity to overcome financial and operational challenges, thus improving efficiency and lowering costs for both parties.
生物银行的财务可持续性最近已成为一个全球性的关键问题,因为生物库难以平衡有限的外部资金和高运营成本。为了最大限度地提高治理和运营效率,病理学设施和伦敦大学学院(UCL)/ UCL 医院健康与疾病研究生物库(“生物库”)已在 UCL 癌症研究所的同一管理层下合并。本文探讨了在 3 年期间(2017-2019 年),病理学设施与生物库之间的运营和财务互动。自 2017 年以来,只有少数请求包括从档案中收集样本或分子生物学服务,而大多数请求包括组织学服务。我们的数据证实了生物库实现财务可持续性的困难。将病理学设施与生物库整合到一个单一的实验室管理和交付基础设施中,被证明是一种有效的管理选择,并为克服财务和运营挑战提供了独特的机会,从而提高了双方的效率并降低了成本。